Senate committee hears emotional debate over bill to require emergency contraception during SANE exams

The Texas Senate Committee on State Affairs spent the longest portion of its Sunday session on House Bill 220, a measure to require health‑care facilities that provide Sexual Assault Nurse Examiner (SANE) exams to offer FDA‑approved emergency contraception to consenting sexual‑assault survivors.

Proponents framed the bill as a time‑sensitive, trauma‑informed medical intervention. "Once that survivor makes a choice to report ... to not give them the immediate choice for preventative medications, quite honestly, is just common sense," said Kim Farbo, who identified herself as working for the Texas Association Against Sexual Assault. Amy Jones, chief executive officer of a Dallas‑area crisis center, said survivors often cannot get emergency contraception after leaving a SANE exam and described cases in which patients were told to fill a prescription off‑site — by then past the clinical window in which the medication is effective.

The bill as filed would codify the Texas Evidence Collection Protocol and require facilities treating sexual‑assault survivors to offer an FDA‑approved emergency contraceptive that prevents pregnancy primarily by delaying ovulation, provided the survivor consents. The committee substitute adds conscience and refusal language aimed at protecting providers who object on moral grounds; critics of the substitute said that change could make the drug unavailable at the point of care.

"If the hospital doesn't have it, it puts these survivors at risk," said Dr. Kara Bridal, a forensic nurse examiner who testified she has cared for thousands of sexual‑assault patients and described cases of minors who became pregnant after an assault because they missed the short treatment window. Bridal and other forensic nurses said many hospitals do not stock emergency contraception for SANE exams and that mandating availability would reduce barriers including time, travel and cost.

Opponents including witnesses from pro‑life organizations said they sympathize with survivors but raised medical and moral concerns about emergency contraceptives. "The FDA label says this product works mainly to prevent ovulation. It may also prevent fertilization or attachment of a fertilized egg," said Dr. John Siegel of Texas Right to Life, summarizing material he submitted. He and other pro‑life witnesses urged insertion of language limiting the required treatments to those that prevent ovulation and do not affect implantation; they also pressed for explicit conscience protections.

Committee members pressed witnesses on the evidence about how emergency contraceptives work, how often they prevent implantation (witnesses disputed this), and whether the substitute's conscience language would effectively deny access at critical moments. Senator Paxton and others asked technical and factual questions; witnesses repeatedly said the difference between "shall" and "may" language in the substitute matters because survivors have only a short window — typically up to 120 hours — to receive effective emergency contraception after an assault.

No final action was taken on HB 220; the bill was left pending while senators directed staff and witnesses to continue refining language and registration statements so positions align with testimony.